Lenalidomide

RED:

NICE TA171: Lenalidomide for treatment of multiple myeloma in people who have received at least 2 prior therapies. (Decision date - July 2019)
NICE TA322: treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (Decision date - October 2014)
NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after treatment with bortezomib. (Decision date - July 2019)
NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma. (Decision date - July 2019)
NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma. (Decision date - May 2020)
NICE TA680: maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (via CDF) (Decision date - April 2021)

DO NOT PRESCRIBE (DNP):

NICE TA454: daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. (Terminated appraisal) (Decision date - August 2017)
NICE TA603: Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma. (Terminated appraisal) (Decision date - October 2019)
NICE TA774: Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) (Decision date - April 2022)

NHS England drug. To be used in line with NHS England commissioning intentions

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions

Derbyshire Medicines Management and Clinical Policies